Some results https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-presents-positive-data-liver-meetingr-2025 Seems like interesting alternative to anti-viral medication with some “side effects” like lowering HBsAg in better way than NUCs. But are those HBsAg declines at least durable ? Any expert could elaborate, please.
Thanks for bringing these trials up on our radar.
Capsid inhibitors are another modality that the scientific community has been developing. It’s another way to target the virus replication apart from the current approaches we have, which hopefully means additive or synergistic effects. We don’t know much about the long-term effects or adverse reactions with these compounds yet, so hard to tell.
We’ve had some conversations about this class of compounds:
Hope this gives you a better idea about their potential.
Cheers,
Thomas